Table 2.

Main comparative features of the therapeutic products containing VWF only

Characteristics	Production method
	Plasma fractionation	Recombinant technology
Commercial name	Wilfactin/Willfact	Vonvendi/Veyvondi
Generic name	Human VWF	Vonicog alfa
Licensing	EMA	FDA and EMA
VWF HMWMs	Deficient	All present
Ultra-large VWF multimers	Absent	Present
VWF:RCo/FVIII:C, IU/dL, ratio	>60	FVIII: only traces

EMA, European Medicines Agency; FDA, US Food and Drug Administration.